source
- Biomanufacturers Redesign Processes to Blend Emergency Vaccine Readiness with Commercial FlexibilityManufacturers are overhauling their production methods to simultaneously improve rapid vaccine deployment for future health crises and maintain flexible, commercially viable manufacturing networks…
- ADARx raises $446 million in one of 2026's largest biotech IPOs as City Therapeutics plans its own listingADARx Pharmaceuticals completed an initial public offering that raised about $446.3 million, exceeding the company’s original target. The shares were priced at $17 each, with 26.25 million shares…